Navigation Links
Plague in Biological Technology

Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza(TM) (Cethromycin) in Community Acquired Pneumonia

... Restanza as a biodefense agent against anthrax, plague and tularemia. On June 2, 2009, the FDA ... and reported from our ongoing pivotal studies in plague and tularemia by the end of 2009. We plan to ... against bioterror agents such as tularemia, plague and melioidosis. In June, the company announced ...

Tips from the journals of the American Society for Microbiology

... New Oral Vaccine May Protect Against Bubonic plague Researchers from the Institut Pasteur in ... ancestor to the highly infectious bubonic plague to develop a potentially safe, efficient and ... the world and can be treated; however, pneumonic plague is almost always fatal within 3 days of ....

UCF professor develops vaccine to protect against black plague bioterror attack

... survived this challenge with no traces of the plague in their bodies. The rats were exposed to a heavy ... and then you convert them into capsules." The plague had a deadly impact on early Europe, it continues ... Organization reports at least 2,000 cases of the plague annually. The most recent outbreak in 2005 killed ...

Tips from the journals of the American Society for Microbiology

... New Oral Vaccine May Protect Against Bubonic plague Researchers from the Institut Pasteur in ... ancestor to the highly infectious bubonic plague to develop a potentially safe, efficient and ... the world and can be treated; however, pneumonic plague is almost always fatal within 3 days of ....

UCF professor develops vaccine to protect against black plague bioterror attack

... survived this challenge with no traces of the plague in their bodies. The rats were exposed to a heavy ... and then you convert them into capsules." The plague had a deadly impact on early Europe, it continues ... Organization reports at least 2,000 cases of the plague annually. The most recent outbreak in 2005 killed ...

Tips from the journals of the American Society for Microbiology

... New Oral Vaccine May Protect Against Bubonic plague Researchers from the Institut Pasteur in ... ancestor to the highly infectious bubonic plague to develop a potentially safe, efficient and ... the world and can be treated; however, pneumonic plague is almost always fatal within 3 days of ....

PharmAthene Closes Acquisition of Avecia Biodefense Vaccines Business Unit

... anthrax vaccine -- A recombinant dual antigen plague vaccine manufactured in E coli -- A third ... associated with its rPA anthrax vaccine and plague vaccine as well as certain government contracts ... its requirements for the rPA anthrax and plague vaccines. On March 28, 2008, Avecia received a ...

PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia

... (rPA) anthrax vaccine, a recombinant dual antigen plague vaccine, and a third generation rPA anthrax ... to Avecia's rPA anthrax vaccine programs and plague vaccine programs. Approximately 50 employees from ... contracts for the anthrax rPA vaccines and the plague vaccine, and royalties on sales to the ...

Advanced Life Sciences Announces Second Quarter 2008 Financial Results

... of Defense DTRA contract to study cethromycin in tularemia, plague and melioidosis for up to $3.8 million; * Submitted funding ... A and B bioterror threats such as inhalation anthrax, tularemia, plague and melioidosis; * Published data in Journal of Antimicrobial ...

PharmAthene Reports Second Quarter 2008 Financial and Operational Results

... vaccine, as well as RypVax(TM), the Company's recombinant dual antigen plague vaccine. Research and development expenses were $11.2 million and $4.0 ... nerve agents -- RypVax(TM) -- a recombinant dual antigen vaccine for plague -- a third generation rPA anthrax vaccine. For more information about ...

PharmAthene Reports First Quarter 2008 Financial Results

... a chemical nerve agent bioscavenger, Protexia(R), and a novel dual antigen plague vaccine. Many of these programs are poised to achieve important milestones ... nerve agent poisoning; RypVax(TM), a recombinant dual antigen plague vaccine; and finally, third generation rPA anthrax vaccine technology. For ...

PharmAthene Reports Year-End 2007 Financial Results

... recombinant Protective Antigen (rPA) anthrax vaccine, a novel dual antigen plague vaccine, RypVax(TM), and third generation anthrax vaccine technology. On ... of Defense (DoD) and that the DoD had decided not to fund Avecia's plague vaccine candidate beyond the current contractual commitments. The parties ...

NASA technology helps predict and prevent future pandemic outbreaks

... Colorado, New Mexico, Arizona, and Utah, is a highly susceptible area for plague and Hanta virus outbreaks, and by understanding the mixture of vegetation, ... vectors within the region and the threat they cause to humans. Because plague is also considered a bioterrorism agent, NASA surveillance systems enable ...

PharmAthene to Host Second Quarter 2009 Conference Call and Webcast on Thursday, August 13, 2009

... and treatment of morbidity and mortality associated with exposure to chemical nerve agents RypVax(TM) -- a recombinant dual antigen vaccine for plague For more information about PharmAthene, please visit www.PharmAthene.com . ...

PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants

... of morbidity and mortality associated with exposure to chemical nerve agents RypVax(TM) - a recombinant dual antigen vaccine for plague For more information about PharmAthene, please visit www.PharmAthene.com. Statement on Cautionary Factors Except for the ...

Dow AgroSciences, NemGenix Establish New Collaboration in Plant Biotechnology

... capitalizes on the strengths of both Dow AgroSciences and NemGenix to develop next-generation technology to help combat parasitic nematodes, which plague millions of crop acres across the globe," said Daniel R. Kittle, Ph.D., vice president of R&D for Dow AgroSciences. "Dow AgroSciences is ...

PharmAthene's 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review

... treatment of morbidity and mortality associated with exposure to chemical nerve agents RypVax(TM) - a recombinant dual antigen vaccine for plague For more information about PharmAthene, please visit www.PharmAthene.com . Statement on Cautionary Factors Except for ...

Assessment of safety and efficacy of human embryonic stem cell therapy

... discovery over a decade ago, hESCs have been considered a promising source of replacement cells for clinical studies. However, problems continue to plague clinical translation, including the risk of teratoma formation and the need for powerful drugs to overcome the problem of immune rejection. Until ...

invivodata Announces ePROficiency 2009 Web Seminar Series

... 20 years of research, deliver reliable patient self-reported data by driving patient compliance with the protocol and eliminating recall biases that plague paper-based self-report data. invivodata's solutions include comprehensive trial-support services that facilitate the collection of ePRO data, ...

PharmAthene Reports First Quarter 2009 Financial and Operational Results

... treatment of morbidity and mortality associated with exposure to chemical nerve agents RypVax(TM) - a recombinant dual antigen vaccine for plague For more information about PharmAthene, please visit www.PharmAthene.com . Statement on Cautionary Factors Except for ...

Divergence Receives $1.2 Million in Grants, Including NSF Grant to Fund Continuing Nematode Research in Corn

... "NCGA recognizes the potential value this research could provide our farmers in terms of new, safe approaches to control nematodes that plague corn and other crops," said Dr. Richard Glass, NCGA vice president of research and business development. "We are always seeking solutions ...

PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research

... treatment of morbidity and mortality associated with exposure to chemical nerve agents RypVax(TM) - a recombinant dual antigen vaccine for plague For more information about PharmAthene, please visit www.PharmAthene.com . Statement on Cautionary Factors Except for ...

NanoLogix Begins Construction of Production Facility for Medical Test Kits

... times faster than current Petri plate methods. Using the BNP(TM) they were able to view anthrax cultures in one-quarter of the time, and bubonic plague (Black Death) cultures in half of the time possible with the best traditional methods. The study appears in the current online issue of Letters in ...

New Weapon in BioDefense Research: NanoLogix Kit Speeds Rapid Diagnostics of Anthrax and Bubonic Plague

... Petri technology and will be the kit of choice whenever faster test results are essential." The bacteria responsible for Anthrax and Bubonic plague are category A select agents, due to their capacity to cause illness and death. These micro-organisms are a preferred bio-weapon of terrorists. As ...

PharmAthene Announces $5.5 Million Public Equity Offering

... treatment of morbidity and mortality associated with exposure to chemical nerve agents RypVax(TM) - a recombinant dual antigen vaccine for plague For more information about PharmAthene, please visit www.PharmAthene.com . Statement on Cautionary Factors Except for ...

PharmAthene To Host Year-End 2008 Earnings Conference Call and Webcast on Monday, March 30, 2009

... treatment of morbidity and mortality associated with exposure to chemical nerve agents RypVax(TM) - a recombinant dual antigen vaccine for plague For more information about PharmAthene, please visit www.PharmAthene.com . Contact: Stacey Jurchison ...

SenesTech Scientists Attend International Workshop on Fertility in New Zealand

... the four year history of this annual meeting. SenesTech's initial product, ContraPest(TM), which is being developed to counteract the rice rat plague in the rice producing countries of the world, will dramatically improve rice yields in Southeast Asia by reducing the rice field rat population. Over ...

invivodata and PRO Consulting to Present at International Industry Events

... 20 years of research, deliver reliable patient self-reported data by driving patient compliance with the protocol and eliminating recall biases that plague paper-based self-report data. invivodata's solutions include comprehensive trial-support services that facilitate the collection of ePRO data, ...

PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting

... treatment of morbidity and mortality associated with exposure to chemical nerve agents RypVax(TM) - a recombinant dual antigen vaccine for plague For more information about PharmAthene, please visit www.PharmAthene.com . Statement on Cautionary Factors Except for the ...

Advanced Life Sciences Announces 2008 Fourth Quarter and Full Year Financial Results

... development of cethromycin as a potential broad-spectrum medical countermeasure against bioterror agents such as tularemia, plague and melioidosis; * Establishment of a strategic relationship with Inventiv Health to support pre-commercialization activities; ...

ECBC's Environmental BioMonitoring Laboratory Focuses on the Future

... Sherlock Bioterrorism Library. In less than 10 minutes, the library can identify extract from anthrax, brucellosis, glanders, tularemia, melioidosis, plague and 15 challenge organisms. EBML serves as a leading technical resource and "go-to lab" that addresses environmentally-related ...

Clemson researchers advance nanoscale electromechanical sensors

... between hydrogen and deuterium gas, very similar isotopes of the same element. Since the whole process is electrical, the size limitations that plague competing detection methods are not a problem here. The cantilevers can be shrunk down to the nano-scale and the operating electronics can be ...

Pharmathene Reports Third Quarter 2008 Financial and Operational Results

... of morbidity and mortality associated with exposure to chemical nerve agents -- RypVax(TM) - a recombinant dual antigen vaccine for plague -- a third generation rPA anthrax vaccine. For more information about PharmAthene, please visit http://www.PharmAthene.com . Statement on ...

Clemson researchers advance nanoscale electromechanical sensors

... between hydrogen and deuterium gas, very similar isotopes of the same element. Since the whole process is electrical, the size limitations that plague competing detection methods are not a problem here. The cantilevers can be shrunk down to the nano-scale and the operating electronics can be ...

Katrina Proven Certified Organic Toxic Mold Remedy Now Available for Mold Remediation Professionals and Homeowners

... mold remedy for mold removal and mold abatement exploiting the same technology that was used effectively on the toxic mold that spread like the plague in the wake of hurricane Katrina. Now professionals and homeowners alike can have a safe all natural alternative to chemical biocides or bleach for ...

US College Students Needing TB Testing Now Have the Benefit of QFT(TM)

... to cross-reactivity with BCG vaccine and commonly encountered environmental non-tuberculous mycobacteria. False-positive TST responses particularly plague students from high TB incidence countries as many of them are vaccinated with BCG at birth. Reading a TST response is subjective and large ...

Advanced Life Sciences Awarded U.S. Department of Defense Biodefense Contract Valued at up to $3.8 Million

... of DTRA funds are available over a nine-month base period to initiate NDA-enabling studies measuring cethromycin's efficacy in treating tularemia and plague as well as studies to measure cethromycin's efficacy in treating melioidosis. The remaining $2.0 million may be awarded over the ensuing 15 months ...

Lord Lewis Moonie to Serve as Special UK Government Advisor to PharmAthene

... and treatment of morbidity and mortality associated with exposure to chemical nerve agents -- RypVax(TM) -- a recombinant dual antigen vaccine for plague a third generation rPA anthrax vaccine. For more information about PharmAthene, please visit http://www.PharmAthene.com . Statement on ...

Nanowires may boost solar cell efficiency, UC San Diego engineers say

... in February 2008. If you provide electrons with a defined pathway to the electrode, you can reduce some of the inefficiencies that currently plague thin-film solar cells made from polymer mixtures. More efficient transport of electrons and holes collectively known as carriers is critical for ...

Advanced Life Sciences Announces First Quarter 2008 Financial Results

... of Health and Human Services to fund the advanced development of cethromycin in combating bioterror agents such as anthrax, tularemia, plague and Burkholderia pseudomallei; * Initiate enrollment by the end of the summer in Phase I/II dose-escalating study to assess the safety, ...
Other Contents
(Date:7/10/2014)... N.Y. , July 2, 2014 It ... (ABD) to announce the appointment of the world-renowned Thoracic ... Board of Directors. Dr. Ginsburg, with over ... facilities: NY Presbyterian Hospital and Good Samaritan Regional Medical ... Pacemaker since the late 1980,s and is considered an ...
(Date:7/10/2014)... 2014 According to the new ... And Area), Material (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), ... Banking & Finance), and Geography - Global Trends & ... global Fingerprint Sensors Market is projected to cross $14.35 ... 16.8% from 2014 to 2020. Browse more ...
(Date:7/10/2014)... 7, 2014 Fingerprint Cards, (FPC,s) new ... win (DW). A Chinese Top 5 smartphone OEM has selected ... mass production in October 2014.   FPC is ... smartphone OEM, which has a planned date for the start ... volume for this phone of 3 million units. The Chinese ...
Breaking Biology News(10 mins):Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3FPC Wins DW for 1021 Touch Sensor for Flagship Smartphone from Chinese Top 5 Smartphone OEM 2
(Date:7/12/2014)... 12, 2014 The rise in the ... for new advanced network architectures to suit the upsurge. ... industry with increasing cloud storage technologies. The data traffic ... more mobility devices. This has resulted in larger and ... driving forces for the SDN market. , The North ...
(Date:7/12/2014)... Dennis Thompson HealthDay Reporter ... way to guarantee that a surgical technique used to grind ... increase the risk of spreading cancer to other parts of ... advisory panel to the Food and Drug Administration also said ... power morcellation -- should sign a written consent stating that ...
(Date:7/12/2014)... Dallas, TX (PRWEB) July 12, 2014 ... training market research report, ‘cognitive assessment and ... able to monitor, assess, train, or enhance ... several uses such as in dementia screening, ... concussion management, classroom learning, self assessment, brain ...
(Date:7/12/2014)... The Security Analytics market is estimated ... million by 2019, at an expected CAGR of 9.7% ... to counter the increasing number of security breaches, continued ... defense systems in organizations are enormous. Vendors in the ... existing architecture to develop better and more secure systems. ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 Tylenol ... continue to move forward in the federal multidistrict ... of Pennsylvania, Bernstein Liebhard LLP reports. According to ... Judge Lawrence F. Stengel has ordered the deposition ... Judge Stengel found that the witness’s testimony concerning ...
Breaking Medicine News(10 mins):Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 4Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 5Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 2Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 2Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 5Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4
Other TagsOther Tags